Skip to Content
 

News: Gastrointestinal Cancer Research Program

SMAD4 clue to colon cancer

Friday, July 6th, 2018

A recent study has linked inflammation-driven carcinogenesis in the colon to loss of an important signaling protein called SMAD4.

Agreement renewal bolsters liver tumor research

Friday, April 13th, 2018

Sirtex Medical Ltd. has renewed a grant award to Dan Brown, MD, professor of Radiology and Radiological Sciences and chief of Interventional Oncology, and his Vanderbilt Health colleagues, for a research program designed to treat patients with liver tumors that cannot be addressed with surgery.

Peek named to serve on NIDDK Advisory Council

Thursday, March 22nd, 2018

Richard Peek, MD, director of the Vanderbilt Digestive Disease Research Center (VDDRC) and chief of the Division of Gastroenterology, Hepatology and Nutrition, has been appointed to serve on the advisory council of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

VUMC researchers find a way to ‘starve’ cancer

Thursday, January 18th, 2018

Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.

Research sheds light on how microtubules are assembled

Friday, January 5th, 2018

James Goldenring, MD, PhD and colleagues have made a fundamental advance in understanding how microtubules are assembled. Their finding, published as an Editor’s Pick last month in the Journal of Biological Chemistry, may lead to new ways to control cancer.

Researchers find novel mechanism of resistance to anti-cancer drugs

Friday, October 20th, 2017

The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors with genetic mutations that make them resistant to these anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or the cancers develop resistance during treatment.

Acid reflux cancer link

Sunday, September 17th, 2017

In a study published in the journal Scientific Reports, Alexander Zaika, Ph.D. and coworkers show that DNA damage in the esophageal cells caused by acidic bile reflux (BA/A) activates enzymes called NADPH oxidases in the mitochondria, the cell’s power house, to release highly reactive-oxygen species (ROS).

Fatty acids and adenoma risk

Monday, August 28th, 2017

Dietary intake of polyunsaturated fatty acids (PUFAs) has been associated with risk of colorectal cancer, with omega-6 PUFAs increasing and omega-3 PUFAs decreasing risk. Most studies, however, have relied on questionnaires to assess consumption of fatty acids, and results have been inconsistent. Harvey Murff, M.D., and colleagues have studied a blood-based biomarker of PUFA intake. […]

Early drivers of gastric cancer

Friday, August 11th, 2017

Gastric cancer – a leading cause of cancer-related deaths worldwide – is commonly diagnosed at a late stage when most patients have a poor prognosis. Wael El-Rifai, M.D., Ph.D., and colleagues are exploring the molecular alterations that drive gastric carcinogenesis, to improve early detection, treatment and prevention. They previously showed that knocking out (eliminating) the […]

Kachnic named one of the ‘Women to Watch’ in health care

Thursday, July 13th, 2017

Lisa Kachnic, M.D., Cornelius Vanderbilt Chair in Radiation Oncology and chair of the Department of Radiation Oncology at Vanderbilt University Medical Center (VUMC), has been named one of the “Women to Watch” in health care by Nashville Medical News. Lisa Kachnic, M.D. Kachnic is among 10 women in the Class of 2017 recognized by the health […]

Next Page »